Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Zheleznyak

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 18, 2008
Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumorsThaddeus J Wadas, Martin Eiblmaier, Alexander Zheleznyak, et al.
Research Square|June 5, 2025
Advanced Quantification Pipeline Reveals New Spatial and Temporal Tumor Characteristics in Preclinical Multiple MyelomaZhixin Sun, Jacqueline Godbe, Alexander Zheleznyak, et al.
Molecular Pharmaceutics|July 25, 2014
Evaluation of (89)Zr-pertuzumab in Breast cancer xenograftsBernadette V Marquez, Oluwatayo F Ikotun, Alexander Zheleznyak, et al.
Plos One|February 15, 2013
Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myelomaDeepti Soodgupta, Michelle A Hurchla, Majiong Jiang, et al.
Nuclear Medicine and Biology|July 4, 2016
Imaging of hypoxia in mouse atherosclerotic plaques with (64)Cu-ATSMXingyu Nie, Gwendalyn J Randolph, Andrew Elvington, et al.
Molecular Imaging and Biology|August 20, 2011
Integrin α(v)β₃ as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulationAlexander Zheleznyak, Thaddeus J Wadas, Christopher D Sherman, et al.
EJNMMI Research|July 31, 2025
Advanced quantification pipeline reveals new spatial and temporal tumor characteristics in preclinical multiple myelomaZhixin Sun, Jacqueline M Godbe, Alexander Zheleznyak, et al.
Theranostics|August 2, 2021
Orthogonal targeting of osteoclasts and myeloma cells for radionuclide stimulated dynamic therapy induces multidimensional cell death pathwaysAlexander Zheleznyak, Matthew Mixdorf, Lynne Marsala, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 13, 2012
Molecular imaging of very late antigen-4 (α4β1 integrin) in the premetastatic nicheMonica Shokeen, Alexander Zheleznyak, Jessica M Wilson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 16, 2011
In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancerKimberly A Lears, Riccardo Ferdani, Kexian Liang, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 18, 2008
Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumorsThaddeus J Wadas, Martin Eiblmaier, Alexander Zheleznyak, et al.
Research Square|June 5, 2025
Advanced Quantification Pipeline Reveals New Spatial and Temporal Tumor Characteristics in Preclinical Multiple MyelomaZhixin Sun, Jacqueline Godbe, Alexander Zheleznyak, et al.
Molecular Pharmaceutics|July 25, 2014
Evaluation of (89)Zr-pertuzumab in Breast cancer xenograftsBernadette V Marquez, Oluwatayo F Ikotun, Alexander Zheleznyak, et al.
Plos One|February 15, 2013
Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myelomaDeepti Soodgupta, Michelle A Hurchla, Majiong Jiang, et al.
Nuclear Medicine and Biology|July 4, 2016
Imaging of hypoxia in mouse atherosclerotic plaques with (64)Cu-ATSMXingyu Nie, Gwendalyn J Randolph, Andrew Elvington, et al.
Molecular Imaging and Biology|August 20, 2011
Integrin α(v)β₃ as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulationAlexander Zheleznyak, Thaddeus J Wadas, Christopher D Sherman, et al.
EJNMMI Research|July 31, 2025
Advanced quantification pipeline reveals new spatial and temporal tumor characteristics in preclinical multiple myelomaZhixin Sun, Jacqueline M Godbe, Alexander Zheleznyak, et al.
Theranostics|August 2, 2021
Orthogonal targeting of osteoclasts and myeloma cells for radionuclide stimulated dynamic therapy induces multidimensional cell death pathwaysAlexander Zheleznyak, Matthew Mixdorf, Lynne Marsala, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 13, 2012
Molecular imaging of very late antigen-4 (α4β1 integrin) in the premetastatic nicheMonica Shokeen, Alexander Zheleznyak, Jessica M Wilson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 16, 2011
In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancerKimberly A Lears, Riccardo Ferdani, Kexian Liang, et al.
Pageof 3